Droperidol cut ER stays in half for cannabinoid hyperemesis syndrome patients
Patients treated with droperidol for CHS had a median ER stay of 6.7 hours versus 13.9 hours for those receiving standard antiemetics.
Quick Facts
What This Study Found
Droperidol-treated CHS patients had significantly shorter hospital stays (6.7 vs. 13.9 hours, p=.014), needed fewer antiemetic doses overall, and used half as much ondansetron and metoclopramide as the non-droperidol group.
Key Numbers
689 records screened, 76 met CHS criteria; droperidol group: median stay 6.7 hours, median 137 min to discharge after last dose; no droperidol: median stay 13.9 hours, 185 min to discharge; most common droperidol dose 0.625 mg IV.
How They Did This
Retrospective review of 689 electronic medical records from a single tertiary hospital (2006-2016), identifying 76 presentations meeting CHS diagnostic criteria. Compared 37 droperidol-treated vs. 39 non-droperidol presentations.
Why This Research Matters
CHS is increasingly common and standard antiemetics are largely ineffective. Droperidol offers a potential targeted treatment that could significantly reduce ER resource use and patient suffering.
The Bigger Picture
Between droperidol and benzodiazepines, clinicians now have two pharmacological approaches to CHS that appear to outperform traditional antiemetics. This represents a shift in how this syndrome should be managed in emergency departments.
What This Study Doesn't Tell Us
Retrospective, single-center study. No randomization. Droperidol group selection may have been influenced by clinician experience or patient severity. Relatively small sample (76 presentations).
Questions This Raises
- ?How does droperidol compare head-to-head with benzodiazepines for CHS?
- ?Could early droperidol administration prevent prolonged ER stays?
Trust & Context
- Key Stat:
- 6.7 vs. 13.9 hours ER stay
- Evidence Grade:
- Moderate: retrospective study with significant findings, but non-randomized design.
- Study Age:
- Published in 2019.
- Original Title:
- The utility of droperidol in the treatment of cannabinoid hyperemesis syndrome.
- Published In:
- Clinical toxicology (Philadelphia, Pa.), 57(9), 773-777 (2019)
- Authors:
- Lee, Carl, Greene, Shaun L(3), Wong, Anselm
- Database ID:
- RTHC-02130
Evidence Hierarchy
Looks back at existing records to find patterns.
What do these levels mean? →Frequently Asked Questions
What is droperidol?
Droperidol is an antipsychotic/antiemetic medication. In this study, low doses (typically 0.625 mg IV) were effective for CHS when standard anti-nausea drugs failed.
Why don't regular anti-nausea drugs work for CHS?
CHS involves cannabinoid receptor dysregulation rather than the typical nausea pathways targeted by standard antiemetics like ondansetron.
Read More on RethinkTHC
- cannabis-cardiovascular-heart-risk-stroke
- cannabis-heart-cardiovascular-risk
- coughing-up-stuff-after-quitting-weed
- lung-recovery-after-quitting-smoking-weed
- lung-recovery-quitting-weed
- quitting-weed-female-hormones
- quitting-weed-weight-gain-loss-diet-appetite
- sex-after-quitting-weed
- weed-DUI-driving-impaired-cannabis-laws
- weed-acne-skin
- weed-fertility-sperm
- weed-gut-digestion-problems
- weed-heart-health
- weed-testosterone-levels
Cite This Study
https://rethinkthc.com/research/RTHC-02130APA
Lee, Carl; Greene, Shaun L; Wong, Anselm. (2019). The utility of droperidol in the treatment of cannabinoid hyperemesis syndrome.. Clinical toxicology (Philadelphia, Pa.), 57(9), 773-777. https://doi.org/10.1080/15563650.2018.1564324
MLA
Lee, Carl, et al. "The utility of droperidol in the treatment of cannabinoid hyperemesis syndrome.." Clinical toxicology (Philadelphia, 2019. https://doi.org/10.1080/15563650.2018.1564324
RethinkTHC
RethinkTHC Research Database. "The utility of droperidol in the treatment of cannabinoid hy..." RTHC-02130. Retrieved from https://rethinkthc.com/research/lee-2019-the-utility-of-droperidol
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.